LuxExperience BV LUXE 深 沪
已收盘 04-02 16:00:00 美东时间
7.79
+0.030
+0.39%
华盛通- 最 高7.96
- 今 开7.68
- 成交量 13.92万股
- 最 低 7.55
- 昨 收 7.76
- 总市值 10.69亿
- 52周最高 20.60
- 市盈率 静 1.27
- 换手率 0.10%
- 52周最低 6.95
- 委 比 -81.82%
- 总股本 1.37亿
- 历史最高 33.15
- 量 比 0.65
- 振 幅 5.28%
- 历史最低 6.95
- 每 手 1
- 风险率 0.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅216.49%！杰富瑞上调BioAge Labs目标价至62美元，评级升至"买入"
今日重点评级关注：杰富瑞：上调BioAge Labs评级至"买入"，目标价从9美元升至62美元；RBC Capital：维持COMPASS Pathways Plc Sponsored ADR"跑赢大市"评级，目标价从21美元升至22美元
02-19 16:21
美股周涨跌榜 | 绩优股霸屏！IPG光电涨超40%，Q4营收同比增加17%；康耐视科技涨近39%
绩优股霸屏！IPG光电涨超40%，Q4营收同比增加17%；康耐视科技涨近39%，Q4业绩超出市场预期；华仕伯涨近54%，有望获Transocean以58亿美元收购>>
02-14 10:36
美股大行评级 | AppLovin评级分歧大！高盛等4家下调，韦德布什上调；HubSpot、休曼纳公司、Shopify、Unity、Paycom Software等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从39美元升至47美元；HC Wainwright & Co.：维持Agios制药"买入"评级，目标价从62美元升至65美元
02-13 15:30
This Shopify Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a comple...
02-12 21:37
JP Morgan Upgrades LuxExperience to Overweight, Raises Price Target to $14
JP Morgan analyst Matthew Boss upgrades LuxExperience (NYSE:LUXE) from Neutral to Overweight and raises the price target from $9 to $14.
02-12 19:37
美股牛股 | 生物技术公司EVMN飙涨超70%！新药用于治疗特应性皮炎的临床试验取得积极成果；ICHR涨超32%
生物技术公司EVMN飙涨超70%！新药用于治疗特应性皮炎的临床试验取得积极成果；ICHR涨超32%，Q4收入2.24亿美元超预期>>
02-11 15:44
LuxExperience shares are trading higher after the company reported better-than-expected Q2 sales results.
LuxExperience shares are trading higher after the company reported better-than-...
02-11 00:06
Datadog, Spotify, Marriott, Ferrari And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones gaining around 200 points on Tuesda...
02-10 23:56
Earnings Breakdown: LuxExperience Q2
LuxExperience (NYSE:LUXE) released its Q2 earnings on Tuesday, February 10, 202...
02-10 19:50
LuxExperience Q2 EPS $(0.17) Misses $(0.11) Estimate, Sales $753.113M Beat $733.200M Estimate
LuxExperience (NYSE:LUXE) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.11) by 54.55 percent. This is a 230.77 percent decrease over earnings of $0.13 per share from
02-10 19:48
